A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

Safety assessed by incidence of serious adverse events

To assess incidence of serious adverse events as a criteria of safety variables.

Time frame: Up to Week 12

Safety assessed by incidence of adverse drug reactions

To assess incidence of adverse drug reactions as a criteria of safety variables.

Time frame: Up to Week 12

Safety assessed by laboratory values and changes from baseline over time

To assess profile of laboratory value transition and potential clinical significance as a criteria of safety variables. The investigators will assess the severity and clinical relevance, and will report as an adverse event as necessary.

Time frame: Up to Week 12

Safety assessed by vital signs: Blood pressure (sitting)

To assess blood pressure as a criteria of safety variables

Time frame: Up to Week 12

Safety assessed by vital signs: Pulse rate (sitting)

To assess pulse rate as a criteria of safety variables

Time frame: Up to Week 12

Safety assessed by 12-lead electrocardiogram

To assess 12-lead electrocardiogram as a criteria of safety variables

Time frame: Up to Week 12

Safety assessed by body weight

To assess body weight as a criteria of safety variables

Time frame: Up to Week 12

Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)

To assess MADRS as a criteria of efficacy variables